Hodgkin lymphoma survivors face twice the risk of death compared to average American adult
Adults who survive Hodgkin lymphoma (HL) for at least five years face increased risk of death from non-cancer conditions and cardiovascular disease
Study reveals need for lifelong survivorship care for patients with HL
Adults who have survived Hodgkin lymphoma (HL) for at least five years face significantly elevated long-term health risks, according to a new study led by researchers at The University of Texas...
Donor cord blood composition may influence CAR NK cell therapy outcomes
CAR NK cell therapy is a novel immunotherapy made from natural killer (NK) cells engineered to better recognize and eliminate cancer cells
At...
Novel antibody-drug conjugate eliminates residual cancer cells in majority of patients with B-cell ALL
Seventy percent of patients had residual levels of cancer cells eliminated
Clearing residual cancer cells is a strong predictor...
Low-intensity combination therapy yields strong outcomes in hard-to-treat AML
Researchers combined an alternating regimen of lower-intensity therapy with a targeted agent in older or medically fragile patients with newly diagnosed AML
Study found 84% of patients achieved remission
Sixty percent of all cases of AML are in people aged 65 and older
A novel lower-intensity treatment yielded high rates of remission in older or medically fragile patients with acute myeloid leukemia (AML), according to researchers...
Novel combination therapy yields high response rates in early-stage classical Hodgkin lymphoma
Phase 2 trial evaluated abbreviated chemotherapy plus brentuximab vedotin and nivolumab
Combination achieved complete response in&...
FLAG-based regimen delivers strong outcomes in subtype of acute myeloid leukemia
Highest reported five-year, relapse-free survival and overall survival rates, especially with FLAG-GO
<...
Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer
Phase II study evaluates treatment for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare, aggressive blood cancer
The...
First-in-human study finds novel immune cell therapy is safe and effective in advanced lymphoma
The novel cell therapy, called RB-1355, appears safe and well tolerated
RB-1355 offers unique advantages, such as being ready in about one week...
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy
More than 90% of patients had a complete response to novel treatment combination
After two years, 97% of patients remained...
Dual-antigen targeting of large B-cell lymphoma shows promise in reducing relapse
Large B-cell lymphoma (LBCL) is an aggressive blood cancer with few treatment options
CAR T cell therapy targeting...
Novel targeted therapy regimens show promise in aggressive AML subtype
MECOM-rearranged acute myeloid leukemia (AML) is an aggressive and hard-to-treat leukemia
Researchers combined three inhibitors...
ASH 2025: New data highlights promise of pivekimab sunirine in two aggressive blood cancers
Two clinical studies demonstrate high response rates by patients with two hard-to-treat and aggressive blood cancers
Pivekimab...
ASH 2025: Researchers identify CD40 as potential biomarker for a type of nodal T cell lymphoma
Researchers characterized the microenvironment of a nodal T cell lymphoma that is difficult to diagnose and treat
The study...
ASH 2025: Shorter azacitidine regimen safely improves outcomes in lower-risk MDS patients
Azacitidine is a type of targeted therapy known as a hypomethylating agent, commonly used in treating myelodysplastic syndromes (MDS)...
ASH 2025: Results show long-lasting benefits of CAR T cell therapy for hard-to-treat lymphoma
Lisocabtagene maraleucel (liso-cel), a CAR T cell therapy, achieved an overall response rate of 97% in the TRANSCEND FL study
Durable...
ASH 2025: New MD Anderson-developed antibody boosts immune response against blood cancers and solid cancers
New investigational therapy 77A is an antibody that converts a cancer survival protein (HSP70) into an immune system trigger
Targeting...
ASH 2025: CAR T cell therapy shows promising Phase II trial results in multiple myeloma
Anito-cel is an experimental CAR T cell therapy for relapsed/refractory multiple myeloma patients
In updated Phase II trial results...
Spatial analysis finds immune-rich pockets in diffuse large B-cell lymphoma tumors with clear treatment potential
Study identified seven distinct and unique microenvironments within diffuse large B-cell lymphoma (DLBCL)
Immune-privileged DLBCLs...
Researchers identify genetic markers that affect treatment outcomes in patients with large B-cell lymphoma
Multiple genetic markers play a key role in the treatment outcomes of patients with large B-cell lymphoma (LBCL) who received chimeric antigen...
Stem cell transplant achieves positive outcomes in second remission for adolescents and young adults with ALL
A new study from The University of Texas MD Anderson Cancer Center and Dana-Farber Cancer Institute, published in American Journal of Hematology...
Patients receiving anti-cancer treatment near end of life experience higher rates of hospitalization, ED and ICU use, and less utilization of hospice
Patients who receive systemic anti-cancer treatment near end of life are more likely to be hospitalized, go to the intensive care unit or...